Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma

Multiple myeloma (MM) is a relapsed and refractory disease, one that highlights the need for developing new molecular therapies for overcoming of drug resistance. Addition of panobinostat, a histone deacetylase (HDAC) inhibitor, to bortezomib and dexamethasone improved progression-free survival (PFS...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JCI Insight
Päätekijät: Imai, Yoichi, Ohta, Eri, Takeda, Shu, Sunamura, Satoko, Ishibashi, Mariko, Tamura, Hideto, Wang, Yan-hua, Deguchi, Atsuko, Tanaka, Junji, Maru, Yoshiro, Motoji, Toshiko
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Clinical Investigation 2016
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5033869/
https://ncbi.nlm.nih.gov/pubmed/27699258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.85061
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia